Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ELOXATIN

« Back to Dashboard
Eloxatin is a drug marketed by Sanofi Aventis Us and is included in two NDAs. It is available from three suppliers. There are four patents protecting this drug and four Paragraph IV challenges.

The generic ingredient in ELOXATIN is oxaliplatin. There are twenty-four drug master file entries for this compound. Five suppliers are listed for this compound. There are four tentative approvals for this compound. Additional details are available on the oxaliplatin profile page.

Summary for Tradename: ELOXATIN

Patents:4
Applicants:1
NDAs:2
Suppliers: see list3

Pharmacology for Tradename: ELOXATIN

Clinical Trials for: ELOXATIN

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759Nov 17, 2006RXYes5,290,961*PED<disabled><disabled>
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021492Aug 9, 2002DISCNNo5,290,961*PED<disabled><disabled>
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759Jan 31, 2005RXYes5,338,874*PED<disabled><disabled>
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759Jan 31, 2005RXYes5,290,961*PED<disabled><disabled>
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759Jan 31, 2005RXYes5,716,988*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ELOXATIN

Drugname Dosage Strength RLD Submissiondate
oxaliplatinInjection5 mg/mL, 40 mL vialEloxatin3/23/2011
oxaliplatinInjection200 mg/40 mLEloxatin7/16/2007
oxaliplatinInjection5 mg/mL, 10 mL and 20 mL vialsEloxatin2/9/2007
oxaliplatinFor Injection50 mg/vial and 100 mg/vialEloxatin2/9/2007
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc